lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展

doi:10.11904/j.issn.1002-3070.2021.06.015

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (6): 562-567.doi: 10.11904/j.issn.1002-3070.2021.06.015

lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展

纪雷¹, 纪道林^1,2, 鲍冬冬¹ 综述, 谭刚¹ 校审

1.哈尔滨医科大学附属第四医院胆胰外科(哈尔滨 150001);
2.哈尔滨医科大学心肌缺血重点实验室

收稿日期:2020-12-01 修回日期:2021-03-31 出版日期:2021-12-28 发布日期:2021-12-17
通讯作者: 谭刚,E-mail:ttgg4698@sina.com
作者简介:纪雷,男,(1993-),硕士研究生,从事肝胆胰脾疾病的研究。
基金资助:
哈尔滨医科大学附属第四医院院基金特别资助金(编号:HYDSYTB201919)

The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma

JI Lei¹, JI Daolin^1,2, BAO Dongdong¹, TAN Gang¹

1. Department of Biliary and Pancreatic Surgery,The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China;
2. Key Laboratory of Myocardial Ischemia,Harbin Medical University

Received:2020-12-01 Revised:2021-03-31 Online:2021-12-28 Published:2021-12-17

摘要/Abstract

摘要： 肝细胞癌(Hepatocellular carcinoma,HCC)是全球最常见和最致命的癌症之一。大多数中晚期患者接受药物为主的治疗,索拉非尼(Sorafenib)作为晚期肝细胞癌的独特靶向药物,在临床上得到了广泛应用。然而,索拉非尼靶向治疗不仅单药有效率低,且耐药性也是亟待解决的大问题。最近研究显示长链非编码RNA(Long non-coding RNA,lncRNA)与肝细胞癌的发生发展、侵袭转移、预后及耐药有着密不可分的联系,并且在耐药研究方面成为新兴热点。本文就lncRNA在肝细胞癌索拉菲尼耐药中的最新发现及调控耐药性的具体机制展开综述。

关键词: 肝细胞癌, 长链非编码RNA, 索拉菲尼, 耐药

Abstract: Hepatocellular carcinoma(HCC)is one of the most common and deadly cancers in the world.Many patients with advanced stage are mainly treated with drugs.Sorafenib,as a unique targeted drug for advanced HCC,has been widely used in clinical practice.However,sorafenib targeted therapy is not only a single drug therapy with low efficiency,but also drug resistance is a big problem that needs to be solved urgently.Recent studies have shown that long non-coding RNA(lncRNA)is closely related to the occurrence,development,invasion and metastasis,prognosis and drug resistance of HCC,and it has become an emerging hot spot in the drug resistance research.This article reviews the latest findings of lncRNAs in the sorafenib resistance of HCC and specific mechanisms of regulating resistance.

Key words: Hepatocellular carcinoma, Long non-coding RNA, Sorafenib, Drug resistance

中图分类号:

R735.7

纪雷, 纪道林, 鲍冬冬, 谭刚. lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 562-567.

JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma[J]. Journal of Practical Oncology, 2021, 35(6): 562-567.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/562

参考文献

1 Bruix J,Han KH,Gores G,et al.Liver cancer:approaching a personalized care[J].J Hepatol,2015,62(Supp1):144-156.
2 Sia D,Villanueva A,Friedman SL,et al.Liver cancer cell of origin,molecular class,and effects on patient prognosis[J].Gastroenterology,2017,152(4):745-761.
3 McGlynn KA,Petrick JL,London WT.Global epidemiology of hepatocellular carcinoma:an emphasis on demographic and regional variability[J].Clin Liver Dis,2015,19(2):223-238.
4 Kim DW,Talati C,Kim R.Hepatocellular carcinoma(HCC):beyond sorafenib-chemotherapy[J].J Gastrointest Oncol,2017,8(2):256-265.
5 Golabi P,Fazel S,Otgonsuren M,et al.Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities[J].Medicine(Baltimore),2017,96(9):e5904.
6 Forner A,Reig M,Bruix J.Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
7 李思维,庞达.长链非编码RNA(lncRNA)在癌症中的作用[J].实用肿瘤学杂志,2019,33(5):471-475.
8 Vitiello M,Tuccoli A,Poliseno L.Long non-coding RNAs in cancer:implications for personalized therapy[J].Cell Oncol,2015,38(1):17-28.
9 Bartonicek N,Maag JL,Dinger ME.Long noncoding RNAs in cancer:mechanisms of action and technological advancements[J].Mol Cancer,2016,15(1):43.
10 Shi T,Gao G,Cao Y.Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics[J].Dis Markers,2016,2016:9085195.
11 Panzitt K,Tschernatsch MM,Guelly C,et al.Characterization of HULC,a novel gene with striking up-regulation in hepatocellular carcinoma,as noncoding RNA[J].Gastroenterology,2007,132(1):330-342.
12 Zhu YJ,Zheng B,Wang HY,et al.New knowledge of the mechanisms of sorafenib resistance in liver cancer[J].Acta Pharmacol Sin,2017,38(5):614-622.
13 Ding B,Lou W,Xu L,et al.Non-coding RNA in drug resistance of hepatocellular carcinoma[J].Biosci Rep,2018,38(5):20180915.
14 Wang Y,Hou J,He D,et al.The emerging function and mechanism of ceRNAs in cancer[J].Trends Genet,2016,32(4):211-224.
15 Lv J,Ma L,Chen XL,et al.Downregulation of LncRNAH19 and MiR-675 promotes migration and invasion of human hepatocellular carcinoma cells through AKT/GSK-3β/Cdc25A signaling pathway[J].J Huazhong Univ Sci Technolog Med Sci,2014,34(3):363-369.
16 Ma H,Yuan L,Li W,et al.The LncRNA H19/miR-193a-3p axis modifies the radio-resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1[J].J Cell Biochem,2018,119(10):8325-8335.
17 Hadji F,Boulanger MC,Guay SP,et al.Altered DNA methylation of long noncoding RNA H19 in calcific aortic valve disease promotes mineralization by silencing NOTCH1[J].Circulation,2016,134(23):1848-1862.
18 Schultheiss CS,Laggai S,Czepukojc B,et al.The long non-coding RNA H19 suppresses carcinogenesis and chemoresistance in hepatocellular carcinoma[J].Cell Stress,2017,1(1):37-54.
19 Hosono Y,Niknafs YS,Prensner JR,et al.Oncogenic role of THOR,a conserved cancer/testis long non-coding RNA[J].Cell,2017,171(7):1559-1572.
20 Cheng Z,Lei Z,Yang P,et al.Long non-coding RNA THOR promotes cell proliferation and metastasis in hepatocellular carcinoma[J].Gene,2018,678:129-136.
21 Cheng Z,Lei Z,Yang P,et al.Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway[J].Gene,2019,684:95-103.
22 Xiang D,Cheng Z,Liu H,et al.Shp2 promotes liver cancer stem cell expansion by augmenting beta-catenin signaling and predicts chemotherapeutic response of patients[J].Hepatology,2017,65(5):1566-1580.
23 Qu L,Ding J,Chen C,et al.Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J].Cancer Cell,2016,29(5):653-668.
24 Li Y,Ye Y,Feng B,et al.Long noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K/Akt Pathway[J].J Cell Biochem,2017,118(12):4498-4507.
25 Yang C,Cai WC,Dong ZT,et al.lncARSR promotes liver cancer stem cells expansion via STAT3 pathway[J].Gene,2019,687:73-81.
26 Yang F,Zhang L,Huo XS,et al.Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans[J].Hepatology,2011,54(5):1679-1689.
27 Ma Y,Cao D,Li G,et al.Silence of lncRNA HEIH suppressed liver cancer cell growth and metastasis through miR-199a-3p/mTOR axis[J].J Cell Biochem,2019,120(10):17757-17766.
28 Shen Q,Jiang S,Wu M,et al.LncRNA HEIH confers cell sorafenib resistance in hepatocellular carcinoma by regulating miR-98-5p/PI3K/AKT pathway[J].Cancer Manag Res,2020,12:6585-6595.
29 Zhang H,Wang Q,Liu J,et al.Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma[J].Oncol Lett,2018,15(6):9377-9384.
30 Xiao J,Lv Y,Jin F,et al.LncRNA HANR promotes tumorigenesis and increase of chemoresistance in hepatocellular carcinoma[J].Cell Physiol Biochem,2017,43(5):1926-1938.
31 Shi Y,Yang X,Xue X,et al.HANR promotes hepatocellular carcinoma progression via miR-214/Ezh2/Tgf-Beta axis[J].Biochem Biophys Res Commun,2018,506(1):189-193.
32 Shi Y,Yang X,Xue X,et al.HANR enhances autophagy-associated sorafenib resistance through miR-29b/ATG9A axis in hepatocellular carcinoma[J].Onco Targets Ther,2020,13:2127-2137.
33 Yang S,Wang X,Contino G,et al.Pancreatic cancers require autophagy for tumor growth[J].Genes Dev,2011,25(7):717-729.
34 Adriaens C,Standaert L,Barra J,et al.P53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity[J].Nat Med,2016,22(8):861-868.
35 Liu F,Chen N,Gong Y,et al.The long non-coding RNA NEAT1 enhances epithelial-to-mesenchymal transition and chemoresistance via the miR-34a/c-Met axis in renal cell carcinoma[J].Oncotarget,2017,8(38):62927-62938.
36 Wang Z,Zou Q,Song M,et al.NEAT1 promotes cell proliferation and invasion in hepatocellular carcinoma by negative regulating miR 613 expression[J].Biomed Pharmacother,2017,94:612-618.
37 Kessler SM,Hosseini K,Hussein UK,et al.Hepatocellular carcinoma and nuclear paraspeckles:induction in chemoresistance and prediction for poor survival[J].Cell Physiol Biochem,2019,52(4):787-801.
38 Niu Y,Tang G,Wu X,et al.LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis[J].Saudi J Gastroenterol,2020,26(4):194-203.
39 He C,Dong X,Zhai B,et al.MiR 21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway[J].Oncotarget,2015,6(30):28867-28881.
40 Wu M,Shen X,Tang Y,et al.Identification and validation of potential key long noncoding RNAs in sorafenib-resistant hepatocellular carcinoma cells[J].PeerJ,2020,8:e8624.
41 Song M,Zhong A,Yang J,et al.Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma[J].Aging(Albany NY),2019,11(22):10422-10453.
42 Guo Z,Zhang J,Fan L,et al.Long noncoding RNA(lncRNA)small nucleolar RNA host gene 16(SNHG16)predicts poor prognosis and sorafenib resistance in hepatocellular carcinoma[J].Med Sci Monit,2019,25:2079-2086.

[1]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[2]	赵浩然, 李满, 张玉宝. 肝细胞癌相关RNA结合蛋白研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 576-579.
[3]	李娜, 邓茜, 蒋建军. NF-κB信号通路在恶性肿瘤化疗耐药中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 580-584.
[4]	贺玲, 姚克铖. 糖基磷脂酰肌醇转酰胺酶与肝癌[J]. 实用肿瘤学杂志, 2021, 35(5): 458-461.
[5]	李钰莹, 张悦. Sirtuins在乳腺癌中作用机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 277-281.
[6]	郑志远,综述,曲国蕃(审校). 长链非编码RNA SNHG3在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 50-54.
[7]	郭飘婷, 邹阳. LncRNA SOX2OT海绵吸附miR-34a促进SOX2表达增强大肠癌多药耐药[J]. 实用肿瘤学杂志, 2020, 34(5): 398-403.
[8]	苗鹏程, 康印东, 李富东, 孟冬冬, 王东星, 常德辉. lncRNA SNHGs在前列腺癌发生发展中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 446-450.
[9]	程月, 张明岩, 张文博, 徐晖. LncRNAs作为ceRNAs在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 451-455.
[10]	仝潇, 邢佳妮, 王丽虹. 长链非编码RNA HCP5通过调控凋亡通路促进三阴性乳腺癌的研究[J]. 实用肿瘤学杂志, 2020, 34(4): 321-327.
[11]	李静, 王玉霞, 陈杰. 长链非编码RNA HOTAIR在宫颈癌中的相关研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 368-371.
[12]	陈都, 钱诚. 乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 382-386.
[13]	梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.
[14]	郭永东, 靳晶, 李利敏, 贺宇彤. 分化拮抗非蛋白质编码RNA(DANCR)在常见恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 69-73.
[15]	刘耿淳, 申良方. 血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 513-518.

lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展

The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价